Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment.

Epilepsy is a chronic medical disorder or condition, usually resulting in unpredictable, unprovoked recurrent seizures that affect a variety of mental and physical functions. It is one of the most common neurological diseases, affecting more than 3 million people in the U.S.1 and about 50 million people worldwide.2 Epilepsy was one of the first brain disorders to be described.3 It was mentioned in ancient Babylon more than 3,000 years ago.3 Through the ages, the strange behavior caused by some seizures has led to the creation of numerous superstitions and prejudices. The term epilepsy is derived from the Greek word epilam-banein, meaning to attack or seize. People once thought that epileptic individuals were being visited by demons or gods. However, in 400 b.c., the early physician Hippocrates suggested that epilepsy was a disorder of the brain—and he was right.3 A person is considered to have epilepsy when two or more unprovoked seizures occur that can’t be explained by a medical condition such as fever or substance withdrawal. Seizures can be the result of a family tendency toward the disease, or they can occur after a brain injury, but the cause of epilepsy is largely unknown.4 Epileptic seizures are manifested by an abnormal, excessive, and hypersynchronous electrical discharge of neurons in the brain.4 Each distinct form of epilepsy has its own natural history and response to treatment.4 This diversity probably reflects the many different underlying causes of epilepsy and the variety of epilepsy syndromes in which the clinical and pathological characteristics are distinctive and suggest a specific underlying etiologic mechanism.5 There are many kinds of seizures, each with characteristic behavioral changes and electrophysiological disturbances that can usually be detected in scalp electroencephalographic (EEG) recordings.4 A seizure is a transient epileptic event, indicating a disturbance in brain function.4 Having a single seizure does not necessarily mean that a person has epilepsy.4,5 Ten percent of adults experience a seizure sometime during their lifetime.1 Seizures can last from a few seconds to a few minutes. Patients and health care professionals do not always recognize the signs or symptoms, which can include convulsions, a loss of consciousness, blank staring, lip smacking, or jerking movements of the arms and legs.1 A seizure has a clear beginning, middle, and end.

[1]  J. Cramer,et al.  Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. , 1985, The New England journal of medicine.

[2]  D. Bergen Antiepileptic Drugs, 4th Ed , 1996, Neurology.

[3]  G. Flint,et al.  Seizures and epilepsy. , 1988, British journal of neurosurgery.

[4]  C. Mathiesen,et al.  Effect of novel AMPA antagonist, NS1209, on status epilepticus An experimental study in rat , 2007, Epilepsy Research.

[5]  E H Reynolds,et al.  The prognosis for seizure control in newly diagnosed epilepsy. , 1984, The New England journal of medicine.

[6]  P. Soares-da-Silva,et al.  Eslicarbazepine acetate (BIA 2-093) , 2011, Neurotherapeutics.

[7]  B. Cooper,et al.  Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. , 1993, The Journal of pharmacology and experimental therapeutics.

[8]  D. Hirtz,et al.  Do seizures in children cause intellectual deterioration? , 1986, The New England journal of medicine.

[9]  J. Bigby Harrison's Principles of Internal Medicine , 1988 .

[10]  M. Brodie,et al.  Special problems: Adults and elderly , 2008 .

[11]  R. Macdonald,et al.  Differential regulation of γ‐aminobutyric acid receptor channels by diazepam and phenobarbital , 1989 .

[12]  M. Brodie,et al.  Selection of antiepileptic drugs in adults. , 2009, Neurologic clinics.

[13]  C M Chee,et al.  Seizure disorders. , 1980, The Nursing clinics of North America.

[14]  T. Tomson,et al.  Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) , 2004, Epilepsy Research.

[15]  W. A. Wilson,et al.  N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): A Novel, Selective KCNQ2/Q3 Potassium Channel Activator , 2008, Molecular Pharmacology.

[16]  Singer Rb Epilepsy and other seizure disorders. , 1992 .

[17]  J. Engel Seizures and Epilepsy , 2012 .

[18]  H. White Comparative Anticonvulsant and Mechanistic Profile of the Established and Newer Antiepileptic Drugs , 1999, Epilepsia.

[19]  C. Stafstrom,et al.  Anticonvulsant and antiepileptic actions of 2‐deoxy‐D‐glucose in epilepsy models , 2009, Annals of neurology.

[20]  K. Holland,et al.  Efficacy, pharmacology, and adverse effects of antiepileptic drugs. , 2001, Neurologic clinics.

[21]  R. Macdonald,et al.  Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. , 1989, Annals of neurology.

[22]  Tw. Rall,et al.  Drugs effective in the therapy of the epilepsies , 1985 .